BRIEF—Teva launches EpiPen Jr generic

Israeli generics giant Teva Pharmaceutical Industries has launched a copy of Mylan’s EpiPen Jr (epinephrine injection, USP) auto-injector in the USA.

The EpiPen Jr product is for a 0.15mg dosage, where the EpiPen is 0.3mg. Teva already has a generic of the stronger drug on the US market.

EpiPen devices are for patients who experience life-threatening allergic emergencies.

Brendan O’Grady, executive vice president and head of North America Commercial, said: “We will continue working to ensure availability of both strengths in the USA and plan to accelerate production to meet the urgent need for this medicine.”